Advertisement Gullapalli Prasanna, Author at Pharmaceutical Business review - Page 4 of 4
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

All articles by Gullapalli Prasanna

FDA grants IND clearance for RiboX’s RXRG001

Dubbed SPRINX-1 Study, the trial aims to assess the safety and efficacy of RXRG001 in treating radiation-induced xerostomia (RIX) [dry mouth] and hyposalivation conditions. A proprietary product created

Lyell signs agreement to acquire ImmPACT Bio

The acquisition will include ImmPACT’s lead product, IMPT-314, aimed at treating haematologic malignancies, such as large B-cell lymphoma. IMPT-314 is a dual-targeting CAR T-cell product candidate that is